Eloralintide in Canada: The Selective Amylin Agonist

Eloralintide, development code LY3841136, is a synthetic peptide developed by Eli Lilly as a long-acting, selective amylin receptor agonist. Amylin, the pancreatic hormone co-secreted with insulin, signals satiety and slows gastric emptying, and its receptors are complexes of the calcitonin receptor with RAMP subunits.[3]

The design goal, stated in the discovery paper, is selective engagement of the amylin receptor complexes, which distinguishes it from earlier analogues whose activity extends across the calcitonin receptor family. For a researcher, selectivity is the point: it is the tool compound for isolating amylin-receptor signaling without confounding pharmacology.

The full sequence and molecular formula have not been placed in the public domain, which is normal for a compound at this stage and is worth stating plainly rather than filling in with a guess.

Research Material

The public record is short and can be read in an afternoon, which is exactly why it is worth reading rather than summarising from secondary sources:

• ·Phase 2, obesity. Billings et al., Lancet 2025: a 48-week multicentre, double-blind, randomised, placebo-controlled trial in adults with obesity or overweight. All treatment arms met the primary endpoint, with mean weight reductions reported from roughly 9.5% to 20.1% against 0.4% for placebo. The most common adverse events were mild to moderate nausea and fatigue.[1]
• ·Phase 1, proof of concept. Bhattachar et al., Diabetes, Obesity and Metabolism 2026: the first-in-human pharmacokinetic and pharmacodynamic characterization supporting once-weekly administration.[2]
• ·Discovery to clinic. The Molecular Metabolism paper covering receptor pharmacology, selectivity profiling and the preclinical package behind the clinical programme.[3]

That is the entire public record. No approval in any jurisdiction, no completed phase 3 dataset, no long-term human safety data. Phase 3 design work was reported as underway during 2026. Anyone writing confident long-term outcome claims about eloralintide is writing fiction.

For a researcher, the thinness of the record is the compound's value rather than its drawback: it is a selective tool for isolating amylin-receptor effects, adjacent to but cleaner than earlier dual-pharmacology analogues. It is not a validated intervention, and it is not authorized for human use anywhere.

The two are the reference points for each other, and the differences are real rather than positional:

• ·Developer. Eloralintide is Eli Lilly; cagrilintide is Novo Nordisk. The programmes are independent.
• ·Pharmacology. Eloralintide is engineered for amylin-receptor selectivity. Cagrilintide is a long-acting amylin analogue with a broader profile across the calcitonin receptor family.
• ·Development stage. Eloralintide has published phase 1 and phase 2 results. Cagrilintide has phase 2 monotherapy data and late-stage combination work.
• ·Public data volume. Cagrilintide substantially more, including combination trials. Eloralintide limited but peer-reviewed.

Chemical Structure

With no established supply history, every eloralintide vial in circulation is only as real as its testing. The risk here is not subtle degradation, it is wholesale substitution with cheaper amylin-adjacent material, and only mass-spectrometry identity testing catches that.

The Eppix standard applies unchanged: every lot tested by Janoshik Analytical, with MS identity, HPLC purity and measured mass, the certificate published before sale and verifiable on the laboratory's own database. The walkthrough for reading one is at how to verify a peptide COA.

Published Certificate

Batch

ELOR-CA-26G-10

Purity (HPLC)

99.810%

Measured content

12.42 mglabelled 10 mg

Laboratory

Janoshik

Verify on the lab’s own databaseAll published certificates

Domestic fulfilment is by Canada Post Xpresspost, typically one to two days nationwide, free over $200, with an Interac e-Transfer discount and mix-and-match pricing at 5 and 10 vials. Current availability is shown on the card below and on the product page, which is where stock should be read from rather than from an article.

The sibling guide is buy cagrilintide in Canada.

Available at Eppix Labs

Buy Eloralintide Canada | Amylin Agonist

10mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $150.00 CADIn stock